NO2 inhalation promotes Alzheimer’s disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication. The gene discussed is MGLL; the disease is early-onset autosomal dominant Alzheimer disease.